Biomerica, Inc. (BMRA)
| Previous Close | 2.9300 |
| Open | 3.0000 |
| Bid | 2.8200 x 3100 |
| Ask | 3.0400 x 1000 |
| Day's Range | 2.7701 - 2.9257 |
| 52 Week Range | 2.6500 - 7.3800 |
| Volume | |
| Avg. Volume | 25,432 |
| Market Cap | 36.154M |
| Beta (5Y Monthly) | -0.68 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5060 |
| Earnings Date | Jan 13, 2022 - Jan 17, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.00 |
- GlobeNewswire
Biomerica to Participate at BTIG Biotech Conference
IRVINE, Calif., June 23, 2022 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced that the Company’s CEO will participate at the 2022 BTIG Biotechnology Conference being held in person in New York City on Monday, August 8th and Tuesday August 9th, 2022. The Company’s CEO will also be available for in-person one-on-one meetings at the conference. About Biomerica NASDAQ: BMRA) Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufa
- ACCESSWIRE
36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022
RALEIGH, NC / ACCESSWIRE / May 16, 2022 / The Spring into Action- Best Ideas Virtual Investor Conference will take place on May 16th \- 20th, 2022, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.The Spring into Action: VIRTUAL begins on Monday, May 16th, 2022, with a Biotech Discovery Day.
- GlobeNewswire
Biomerica Announces CE Mark for Its H. pylori Diagnostic Test, hp+detect™
- Attaining CE Mark is a major step toward commercialization – - World Health Organization (WHO) lists H. pylori among the 16 antibiotic-resistant bacteria that pose the greatest threat to human health and designated H. pylori as a Class 1 carcinogen, meaning that it is a known cause of cancer - - 45% of the population in Europe’s five largest countries are afflicted with H. pylori - IRVINE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provide
